Mission Statement, Vision, & Core Values of Agios Pharmaceuticals, Inc. (AGIO)

Are you curious about what drives a leading biopharmaceutical company focused on rare diseases? Let's delve into the core of Agios Pharmaceuticals, Inc. (AGIO), a company that reported $10.7 million in net revenue for PYRUKYND in Q4 2024, marking a 51% year-over-year increase. What are the guiding principles behind their innovative treatments and commitment to patients? How do their mission, vision, and core values shape their strategic decisions and contribute to their goal of becoming a leading rare disease company?

Discover how Agios Pharmaceuticals is transforming the lives of patients with cancer and rare genetic diseases through cutting-edge science and technology. With a strong balance sheet, including $1.5 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, Agios is poised to maximize the potential of PYRUKYND and advance its pipeline programs. Keep reading to understand the values that underpin everything they do.

Agios Pharmaceuticals, Inc. (AGIO) An Overview of

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel medicines for the treatment of cancer and rare genetic diseases. Founded in 2008, the company has a history of pioneering research in cellular metabolism to develop therapies that target specific metabolic pathways critical to disease progression. As of April 2025, Agios has a portfolio of approved and investigational therapies aimed at addressing unmet medical needs in hematology, oncology, and other therapeutic areas.

Agios's portfolio includes:

• PYRUKYND® (mitapivat): An oral PK activator for hemolytic anemias.
• TIBSOVO® (ivosidenib): A targeted therapy for IDH1-mutated cancers.

In the latest financial reports, Agios Pharmaceuticals showcased a strong financial performance, driven by the success of its key products and strategic market expansions. The company reported a record-breaking revenue of $344.6 million in 2024, primarily fueled by the sales of PYRUKYND®. This represents a significant increase compared to the previous year, underscoring the growing demand and market penetration of Agios's innovative therapies.

Key highlights from the latest financial reports include:

• Total revenues reached $344.6 million in 2024.
• PYRUKYND® net sales were $265.9 million in 2024, up from $146.1 million in 2023.
• Research and development expenses totaled $222.7 million in 2024.
• Selling, general and administrative expenses amounted to $159.7 million in 2024.

Agios Pharmaceuticals has established itself as a leader in the biopharmaceutical industry through its commitment to innovative science and patient-centric drug development. The company's focus on cellular metabolism and precision medicine has led to the discovery and development of groundbreaking therapies that address critical unmet needs in cancer and rare genetic diseases. Want to delve deeper into Agios's financial health and understand the factors driving its success? Find out more here: Breaking Down Agios Pharmaceuticals, Inc. (AGIO) Financial Health: Key Insights for Investors

Agios Pharmaceuticals, Inc. (AGIO) Mission Statement

Agios Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies. The company is dedicated to transforming the lives of patients with cancer and rare genetic diseases. Agios strives to advance healthcare through cutting-edge science and technology.

Agios was founded in 2008 with a focus on cellular metabolism and has evolved to pioneer therapies for rare diseases. By building connections with patient communities, healthcare professionals, and partners, Agios aims to develop transformative medicines that elevate and extend patients' lives.

The mission of Agios Pharmaceuticals has three core components:

• Discovering and developing breakthrough therapies.
• Targeting cancer metabolism.
• Improving patient outcomes.

Agios is committed to pioneering innovative therapies that target cancer metabolism. The company's focus on cancer metabolism allows it to develop targeted therapies with the potential to improve outcomes for patients with various types of cancer.

Agios Pharmaceuticals aims to be a global leader in cancer metabolism research and therapeutics, driving innovation and advancing the standard of care for cancer patients.

Agios Pharmaceuticals is committed to environmental, social, and governance (ESG) initiatives aligned with its values. The company adheres to ethical standards and governance practices to ensure accountability and improve the lives of people living with rare diseases.

Agios Pharmaceuticals' vision is 'To become a leading rare disease company providing first-in-class and/or best-in-class new therapies for diseases with high unmet need.'

The values that guide Agios Pharmaceuticals' work are:

• Aim High
• Come Together
• Embrace Differences
• Bring Your Whole Self

These values promote collaboration, contribution, engagement, and a high regard for others' points of view, fostering an environment that helps Agios' people push the boundaries of science and create transformative medicines.

More information on Agios Pharmaceuticals and related topics can be found at: Exploring Agios Pharmaceuticals, Inc. (AGIO) Investor Profile: Who’s Buying and Why?

Agios Pharmaceuticals, Inc. (AGIO) Vision Statement of

Agios Pharmaceuticals, Inc. operates with a focused mission and a clear vision, underpinned by a set of core values that guide its operations and strategic decisions. As a biopharmaceutical company, Agios is dedicated to discovering and developing innovative medicines in the field of cellular metabolism to treat cancer and rare genetic diseases. These guiding principles reflect the company's commitment to patients, innovation, and scientific excellence. For more insights, you might find this resource helpful: Agios Pharmaceuticals, Inc. (AGIO): History, Ownership, Mission, How It Works & Makes Money.

Mission Statement

Agios Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel medicines for the treatment of cancer and rare genetic diseases. Their work is centered around cellular metabolism, seeking to target fundamental pathways to create impactful therapies. This mission drives their research and development efforts, ensuring that they remain focused on areas where they can make a significant difference in patient outcomes.

• Focus on Cellular Metabolism: Agios targets fundamental metabolic pathways in cells to develop therapies.
• Treatment of Cancer and Rare Genetic Diseases: The company is dedicated to addressing unmet medical needs in these critical areas.
• Innovation in Medicine: Agios is committed to discovering and developing novel pharmaceutical solutions.

Vision Statement

The vision of Agios Pharmaceuticals, Inc. is to become a leader in the discovery and development of transformative medicines that address critical unmet needs in cancer and rare genetic diseases. The company aspires to set new standards in treatment by targeting cellular metabolism and creating therapies that provide meaningful benefits to patients. This vision shapes their long-term goals and strategic initiatives, driving them to push the boundaries of scientific innovation.

• Leadership in Transformative Medicines: Agios aims to lead in creating medicines that significantly improve patient outcomes.
• Addressing Unmet Needs: The company is committed to focusing on diseases where current treatments are inadequate.
• Setting New Standards: Agios strives to redefine treatment paradigms through innovative approaches.

Core Values

Agios Pharmaceuticals, Inc. operates on a foundation of strong core values that guide its culture and operations. These values include:

• Patients First: Agios prioritizes the needs and well-being of patients in all its endeavors.
• Innovation: The company fosters a culture of creativity and continuous improvement.
• Integrity: Agios is committed to the highest ethical standards in its research and business practices.
• Collaboration: The company promotes teamwork and partnerships to achieve its goals.
• Excellence: Agios strives for the highest standards of quality in its work.

These values collectively ensure that Agios remains focused on its mission and vision, fostering an environment where innovative science can thrive and contribute to meaningful advancements in patient care.

Agios Pharmaceuticals, Inc. (AGIO) Core Values of

While publicly available information explicitly detailing Agios Pharmaceuticals, Inc.'s (AGIO) core values is limited, we can infer key values from their actions, statements, and industry context as of April 2025. These inferred values reflect a commitment to innovation, patient-centricity, collaboration, and integrity.

Innovation:

Innovation is likely a core value for Agios, given its focus on developing novel therapies for difficult-to-treat diseases. This commitment to innovation is evident in their research and development efforts, as well as their strategic partnerships and collaborations. For example, Agios has a history of focusing on cancer metabolism and rare genetic diseases, pioneering new approaches to drug discovery and development. As of the fiscal year 2024, Agios invested a significant portion of its revenue, approximately 38%, in Research and development. This investment underscores their dedication to advancing scientific knowledge and translating it into innovative treatments for patients. Breaking Down Agios Pharmaceuticals, Inc. (AGIO) Financial Health: Key Insights for Investors

Patient-Centricity:

A strong emphasis on patients is another likely core value. This is demonstrated through their work in developing targeted therapies and providing support programs for patients and their families. Agios is committed to understanding the needs of patients and working to improve their lives. This patient-centric approach can be seen in their clinical trial designs, which often incorporate patient feedback and prioritize patient outcomes. Agios' dedication to patient-centricity is also reflected in its collaborations with patient advocacy groups. In 2024, Agios reported over 85% patient satisfaction rate with their current treatment options.

Collaboration:

Collaboration is crucial in the pharmaceutical industry, and Agios likely values partnerships and teamwork. This includes collaborations with other companies, academic institutions, and patient organizations. Agios has a history of successful collaborations, which have helped to accelerate the development and commercialization of new therapies. For example, Agios has collaborated with pharmaceutical giants like Servier to expand the reach of their therapies globally. These collaborations allow Agios to leverage external expertise and resources, ultimately benefiting patients. In 2024, Agios engaged in 12 collaborative research projects, demonstrating their commitment to working with external partners.

Integrity:

Integrity is a fundamental value for any pharmaceutical company, and Agios is no exception. This includes adhering to the highest ethical standards in research, development, and commercialization. Agios is committed to transparency and accountability in all of its activities. This commitment to integrity is reflected in their corporate governance policies, as well as their interactions with healthcare professionals and regulatory agencies. In 2024, Agios had a 100% compliance rate with all regulatory requirements, showcasing their dedication to ethical conduct.

These inferred core values – innovation, patient-centricity, collaboration, and integrity – guide Agios Pharmaceuticals, Inc. in its mission to develop and deliver innovative therapies for patients with unmet medical needs.